Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 01, 2026
Why Is Glass House Brands (GLAS) Stock Down -7.66% Today?

Why Is Glass House Brands (GLAS) Stock Down -7.66% Today?

Key Takeaways

  • GLAS shares fell about 7.66% to $5.18, down from the prior session's close of $5.61.
  • The primary catalyst was a sector-wide cannabis selloff after a DEA judge paused the marijuana rescheduling process.
  • A secondary driver was Glass House Brands' announcement of its chief financial officer's planned retirement.
  • The move extends a multi-week slide that has pushed the stock near its 52-week low.
  • Traders are now watching the DEA's mid-October response and the company's next earnings report in November.

Opening Summary

Glass House Brands Inc. (GLAS), an integrated, California-focused cannabis company that cultivates, manufactures, and distributes products under brands such as Glass House Farms, PLUS, Allswell, and Mama Sue, extended its sharp decline in Thursday's trading session. The stock was down roughly 7.66%, trading near $5.18 compared with the prior close of $5.61, continuing a punishing stretch for cannabis equities. Markets pointed primarily to a federal regulatory setback for the industry as a whole, compounded by a leadership transition announcement at the company itself.

Sector-Wide Selloff After DEA Rescheduling Pause

The dominant force behind the decline was a broad risk-off move across cannabis stocks. A Drug Enforcement Administration (DEA) administrative law judge paused the pending proceeding on moving marijuana from Schedule I to Schedule III, following a Government Accountability Office report that flagged gaps in the federal scheduling process. The judge granted a stay requested by parties opposing broader rescheduling and gave the DEA until October 13 to respond on whether to reopen the record.

Investors had treated rescheduling as a near-term catalyst because Schedule III status would lift the onerous Section 280E tax penalty, allowing operators to deduct ordinary business expenses and materially improving earnings and cash flow. The procedural pause pushed expectations for progress further out and triggered heavy selling across multi-state operators and cannabis-focused ETFs. GLAS fell in sympathy with peers such as TRLV and the MSOS ETF, as investors repriced the timeline for federal reform.

CFO Retirement Adds Company-Specific Uncertainty

Compounding the sector pressure, Glass House Brands announced on September 29 the planned retirement of Chief Financial Officer Mark Vendetti, who will remain in the role through March 31, 2027 while the company searches for a successor. Executive departures in the finance function can weigh on sentiment, particularly for a company navigating margin compression and a shrinking revenue base. The announcement added a layer of company-specific uncertainty to an already fragile tape.

Fundamental Backdrop Remains Challenging

The selloff also reflects underlying operational headwinds. In its second quarter, Glass House Brands reported revenue of about $47 million, below prior guidance, in part due to the deconsolidation of retail operations. Gross margin declined sharply versus the prior year as a higher mix of low-value trim sales and elevated production costs pressured profitability. The company generates the bulk of its revenue from low-margin wholesale biomass, and its branded consumer segment remains a small fraction of the business. These fundamentals left the stock vulnerable when regulatory sentiment soured.

Market Context and Trading Activity

Trading activity reflected the intensity of the move. The prior session's volume of more than 5.5 million shares was roughly ten times the stock's average daily volume, signaling broad-based selling rather than isolated positioning. The decline has brought GLAS to the lower end of its range, near its 52-week low around $5.15, and well below its 50-day and 200-day moving averages. The move diverged from the broader equity market, underscoring that the pressure was specific to cannabis and regulatory sentiment rather than a macro-driven risk-off event.

What Comes Next for GLAS

Investors will be watching the DEA's October 13 response on whether the rescheduling record will be reopened, a decision that could set the tone for the sector into the fall. Glass House Brands is also expected to report its next quarterly results on November 11, 2026, with attention on biomass pricing, margin recovery, and any update on the CFO succession process. The company's elevated debt and preferred-stock obligations remain a focus, as does the timeline for interstate and international expansion. Until there is clearer regulatory visibility or a firmer fundamental inflection, volatility in the stock is likely to persist.

Trending AI Robots

For traders seeking a more systematic approach to fast-moving markets, Tickeron's Trending AI Robots page offers a curated view of its strongest-performing AI trading bots. Tickeron provides hundreds of AI-driven trading bots covering thousands of tickers, but only those performing best under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, giving users a range of options to explore. Visit the Trending AI Robots page to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GLAS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


GLAS sees MACD Histogram just turned negative

GLAS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 24, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 35 instances where the indicator turned negative. In 32 of the 35 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GLAS as a result. In 71 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The 50-day moving average for GLAS moved below the 200-day moving average on September 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for GLAS entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

GLAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.889) is normal, around the industry mean (43.873). P/E Ratio (0.000) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.880) is also within normal values, averaging (178.797).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. GLAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.13B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -6%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 27%. RGC experienced the highest price growth at 17%, while LQDA experienced the biggest fall at -62%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 44%. For the same stocks of the Industry, the average monthly volume growth was 55% and the average quarterly volume growth was 1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 63
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 84
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
GLAS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Industry
N/A
Address
3645 Long Beach Boulevard
Phone
+1 212 299-7670
Employees
428
Web
https://www.glasshousebrands.com
Interact to see
Advertisement
I've been following ANTX, a biopharmaceutical company based in Menlo Park, California, that develops novel small molecule therapeutics from its proprietary boron chemistry platform. The focus is on underserved areas like infectious diseases, with the lead candidate epetraborole advancing in Phase 3 trials for non-tuberculous mycobacterial (NTM) lung disease and acute melioidosis. The pipeline also includes AN2-502998 for chronic Chagas disease in preclinical stages, along with programs in oncology.
Tilly's, Inc. (TLYS) operates as a specialty retailer specializing in casual apparel, footwear, accessories, and hardgoods aimed at young men, women, boys, and girls. The company focuses on branded fashion inspired by action sports, surf, and skate culture, offering products like tops, bottoms, swimwear, backpacks, hats, and sunglasses from well-known brands such as Vans and Hurley. With approximately 223 stores in malls and lifestyle centers, complemented by e-commerce through www.tillys.com, Tilly's effectively combines physical and digital sales channels.
Aemetis, Inc. (AMTX) is a renewable natural gas and renewable fuels company focused on developing and commercializing low- and negative-carbon intensity products that replace petroleum-based fuels. The company operates through segments including California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. Its core business model centers on converting agricultural waste—such as dairy manure into biogas and corn/wood waste into ethanol—into high-value biofuels like renewable natural gas (RNG), ethanol, biodiesel, and sustainable aviation fuel precursors.
Silvaco Group, Inc. (SVCO) provides technology computer-aided design (TCAD) software, electronic design automation (EDA) software, and semiconductor intellectual property (SIP) solutions. The company helps semiconductor and photonics firms design, simulate, and optimize processes from atomic-level modeling to complex system-on-chip (SoC) development. Its business centers on licensing software tools and IP blocks, along with engineering services, targeting high-growth areas like AI, power devices, automotive, foundries, and 5G/6G mobile.
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
APTV shares are tumbling approximately 14% in premarket trading on April 1, 2026, representing one of the sharpest single-session losses in the stock's recent history. The primary catalyst is Aptiv's Board of Directors formally approving the long-anticipated spin-off of its Electrical Distribution Systems (EDS) business, now named Versigent, combined with the announcement of a $1.6 billion private offering of senior notes tied to the transaction.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
RH shares are down approximately 17% in premarket trading on April 1, 2026, after closing the previous session at $139.82, with the stock indicated near $115.76 — a decline of roughly $24 per share. The primary catalyst is a significant Q4 fiscal year 2025 earnings miss, with adjusted EPS of $1.53 coming in well below the Wall Street consensus of $2.22 — a 31% negative surprise.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ORIC Pharmaceuticals shares are down approximately 21% in premarket trading on April 1, 2026, from a prior session close of approximately $12.19, placing the premarket price near $9.63. The primary catalyst is the after-market release of Phase 1b dose optimization data for rinzimetostat (ORIC-944) on March 31, alongside the selection of 400 mg once daily as the recommended Phase 3 dose for the Himalayas-1 registrational trial.
Shares of Target Hospitality Corp. (Nasdaq: TH) surged approximately 38% during Wednesday's trading session, climbing from a prior close of $9.28 to approximately $12.81. The primary catalyst is the company's announcement of a landmark multi-year lease and services agreement worth over $550 million with a top-five global hyperscaler to build and operate a data center workforce community in North Texas.
Shares of Turning Point Brands (TPB) are falling sharply intraday on April 1, 2026, shedding approximately 15% from their prior session close of roughly $87.41, placing the stock near $74.30. The primary catalyst is broad investor risk-off selling tied to mounting trade-policy uncertainty ahead of President Trump's sweeping tariff announcements scheduled for April 2 — a day the administration has branded "Liberation Day".
Shares of Philip Morris International fell approximately 8% during intraday trading on April 1, 2026, dropping from a prior close of $165.34 to around $152.11. A sharp, broad-based market selloff — amplified by renewed trade policy tensions — is acting as the primary macro catalyst behind the decline.
WDC shares surged approximately +10% in Wednesday's session, advancing to approximately $296–$297 from a prior close near $269.82 on March 31, 2026. The primary catalyst is a major analyst upgrade: Bernstein raised its rating on Western Digital from Market Perform to Outperform and dramatically doubled its price target to $340 from $170.
I've been following CG Oncology, Inc. (CGON), a late-stage clinical biopharmaceutical company dedicated to developing and commercializing cretostimogene grenadenorepvec. This investigational oncolytic immunotherapy aims to serve as a bladder-sparing therapeutic for patients with non-muscle invasive bladder cancer (NMIBC). The company's focus remains on pushing this intravesical therapy through Phase 3 trials to address high unmet needs in BCG-unresponsive and intermediate-risk NMIBC, where treatments like BCG frequently fall short. In the broader biotech landscape, CG Oncology stands out with cretostimogene's encouraging durability and tolerability, which could position it as a foundational therapy. From what I see, these solid fundamentals—bolstered by strong clinical data and regulatory steps—have directly supported the recent stock price gains amid positive trial developments.